<DOC>
	<DOCNO>NCT01535859</DOCNO>
	<brief_summary>The purpose study determine whether cabergoline effective reduce incidence severity Ovarian Hyperstimulation Syndrome ( OHSS ) , especially severe case ; derive biomarkers risk develop OHSS .</brief_summary>
	<brief_title>Study Cabergoline Prevention Ovarian Hyperstimulation Syndrome ( OHSS ) In Vito Fertilization Cycles Derivation OHSS Biomarkers</brief_title>
	<detailed_description>Severe ovarian hyperstimulation syndrome ( OHSS ) occur 2 % in-vitro fertilisation ( IVF ) cycle , result accumulation fluid peritoneal , pleural pericardial cavity , haemo-concentration resultant venous thromboembolic phenomenon , reduce perfusion vital organ , renal failure , acute respiratory failure , even death . The long term aim develop comprehensive strategy reduce incidence severity OHSS in-vitro fertilisation ( IVF ) cycle . Our short term aim ( 2-3 year ) test ability dopamine receptor agonist cabergoline reduce incidence severity OHSS high risk woman undergo controlled ovarian hyperstimulation ( COH ) fresh IVF cycle reduction vasoactive cytokine level , specifically serum vascular-endothelial growth factor ( VEGF ) . Specifically : 1 . Conduct randomise double-blind placebo-controlled trial woman high risk develop OHSS fresh COH-IVF cycle 2 . Investigate serum follicular fluid level potential biomarkers OHSS .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
	<mesh_term>Cabergoline</mesh_term>
	<criteria>Patients 20 oocyte collect COH gonadotropinreleasing hormone ( GnRH ) agonist antagonist cycle Patients allergy dopamine agonist Patients undergo invitro maturation cycle Patients GnRH analogue use trigger oocyte maturation antagonist cycle</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>